NeOnc Technologies Holdings CEO Amir Heshmatpour purchased 80,000 shares of company stock for $269,082 in early November. This brings his total 2026 open-market acquisitions to 271,000 shares, representing an investment of approximately $1.11 million. The move precedes the company's scheduled data presentations for its NEO100 and NEO212 programs at the Society for Neuro-Oncology Annual Meeting.
CEO Amir Heshmatpour bought 80,000 shares on the open market on November 5, 6 and 9, 2026 for $269,082 (about $3.36 per share), bringing his 2026 open-market purchases to 271,000 shares for roughly $1.11 million of personal funds. Insider buying at these levels is typically read as a management confidence signal for a clinical-stage biotech, and it comes just ahead of the November 13 Society for Neuro-Oncology data presentations. However, the filing itself changes nothing about the company's cash position or clinical results, so the effect is a sentiment nudge rather than a fundamental catalys
- ▲ CEO purchased 80,000 shares for $269,082 on November 5, 6 and 9, 2026
- ▲ 2026 open-market purchases total 271,000 shares (~$1.11 million), 191,000 of them after the August 12 Phase 2a topline announcement
- ▼ NEO100 Phase 2a was a single-arm, open-label study not powered as a confirmatory trial
- ▼ Neither NEO100 nor NEO212 is approved by any regulatory authority and no approval pathway is assured